HBV Cure 2018 – Presentations

 Day 1 - Wednesday 7 November

 Session 1: Modulating approved therapies to achieve HBV Cure

What is the cure rate with current therapies?
Harry Janssen
Toronto General Hospital / University Health Network, Toronto, Canada

 Berg, Thomas 2015Stopping Nucleos(t)ide Analogues:  When is it beneficial, when is it dangerous? 
Thomas Berg
University of Leipzig, Germany
 Boonstra, Andre 2017Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies
Andre Boonstra
Erasmus Medical Center, Rotterdam, The Netherlands
 Session 2: New Endpoints and Biomarkers
 Feld, Jordan 2016 120What are the pros and cons of HBsAg loss as the endpoint for treatment?
Jordan Feld
Toronto Centre for Liver Disease, Toronto, Canada
 Levrero, Massimo 2016 120Can we measure (activity of) cccDNA in the blood?
(Not yet available)

Massimo Levrero
INSERM, Lyon, France
 Gehring, Adam 2014Will HBsAg depletion restore HBV specific immunity?
Adam Gehring
Toronto Centre for Liver Disease, Toronto, Canada
 Session 3: Update on Immune Targets for HBV Therapy 
 Maini, Mala 2016Rationale for modulating innate immunity: TLR, RIG- and others
Mala Maini
University College London, London, UK
 Afdhal, NezamAntiviral effect of the RIG-I agonist, Inarigavir
Nezam Afdhal
Beth Israel Deaconess Medical Center, Boston, USA
 Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model
Yonghong Zhu
Roche Innovation Center Shanghai, Shanghai, China 
 Paulsen, Daniela 2018 120x160Innate activation with Inactivated parapox viruses for HBV therapy - AIC649
Daniela Paulsen
AiCuris, Germany
 Thimme, Robert 2016Rationale for Modulating Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibitor and others
Robert Thimme
University of Freiburg, Freiburg, Germany
 Verdon, Daniel 2018 120x160Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection
Daniel Verdon
University of Auckland, Auckland, New Zealand
 Session 4: Update on Virologic Targets for HBV Therapy

Stephan Locarnini, BSC, PhD, MBBS, FRC

Rationale for different Virological Targets in HBV
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia

 Urban, Stephen, 2016 120x160Clinical progress of the entry inhibitor Myrcludex B
Stephan Urban
University of Heidelberg, Heidelberg, Germany
 Vaillant, Andrew 2018 120x160Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy
Andrew Vaillant
Replicor, Montreal, Canada


Given, Bruce D 2016 120Clinical update on reducing HBV virus and antigen production using RNAi
Bruce Given
Arrowhead, Pasadina, USA


Mendez, Patricia. 2018 120x160Patricia Mendez
Arbutus Biopharma, Warren, USA

 DSC_0689_4Clinical update, antiviral effect and mode of action of capsid assembly modulators
Jeysen Yogaratnam
Janssen Biopharma, South San Francisco, USA
 Colonno, Richard 2018 120x160Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates
Rich Colonno
Assembly Bioscience, San Francisco, USA